What Long COVID Is Teaching Us About ME/CFS

A Familiar Illness in a New Disguise

When millions of people began reporting persistent, disabling symptoms months after their acute COVID-19 infection had resolved, clinicians and researchers faced something seemingly unprecedented. Fatigue that didn't lift. Cognitive difficulties so thick they made reading a paragraph feel like wading through mud. A crushing worsening of symptoms after even minor exertion. Sleep that left people feeling no better than before they closed their eyes. To the wider public, it was shocking. To ME/CFS patients and the doctors who had spent careers trying to help them, it was heartbreakingly recognisable.

Long COVID — formally termed post-acute sequelae of SARS-CoV-2 infection, or PASC — has turned out to share far more than a passing resemblance to ME/CFS. For researchers, that convergence is one of the most significant scientific developments the field has seen in a generation. It does not yet mean answers are imminent, but it has fundamentally changed the landscape in ways that patients who have lived with ME/CFS for years, or decades, deserve to understand.

Shared Hallmarks, Overlapping Diagnoses

The overlap between long COVID and ME/CFS is not merely impressionistic. Studies published since 2021 have found that a substantial proportion of people with long COVID — estimates in peer-reviewed literature have ranged broadly, but credible studies suggest figures commonly between roughly 40 and 60 percent of those with persisting symptoms — meet established diagnostic criteria for ME/CFS, such as the 2015 Institute of Medicine criteria or the International Consensus Criteria. These criteria require, among other things, the hallmark symptom that distinguishes ME/CFS from simple chronic tiredness: post-exertional malaise.

Post-exertional malaise, or PEM, is the worsening of symptoms — physical, cognitive, and immunological — following exertion that would be trivial for a healthy person. It is not mere tiredness after activity. It is a pathological, often delayed response in which the body appears unable to recover normally from even modest effort. A short walk, a phone call, a bout of concentration can trigger what patients call a "crash" — a flare of symptoms that may last days or weeks. PEM is now widely regarded by ME/CFS specialists as the illness's cardinal feature, and it is precisely what separates long COVID patients who meet ME/CFS criteria from those who don't. When long COVID researchers began systematically measuring PEM, they were, in effect, measuring ME/CFS — and the results were illuminating.

The overlap extends to other symptoms too. Unrefreshing sleep — rest that provides no restoration — is reported at high rates in both populations. So is orthostatic intolerance, the dizziness and lightheadedness that emerges when patients sit or stand, pointing to autonomic nervous system dysregulation. Cognitive impairment, widely known as "brain fog," affects both groups in ways that neuropsychological testing confirms go beyond what mood disorders or poor sleep alone can explain. These are not soft complaints. They are measurable, biological, and serious.

The Post-Viral Thread Running Through the History

ME/CFS has almost certainly been with us for a very long time — described under various names, including myalgic encephalomyelitis following outbreaks in the mid-twentieth century, and later as chronic fatigue syndrome in the 1980s after clusters were observed in communities including Incline Village, Nevada. What has always been notable, and consistently under-appreciated by mainstream medicine, is that a large proportion of ME/CFS cases appear to have been triggered by infection. Epstein-Barr virus, human herpesvirus 6 (HHV-6), enteroviruses, and other pathogens have all been investigated as potential triggers, with researchers including John Chia examining enteroviral involvement for many years.

The idea that a virus could, in susceptible individuals, set in motion a prolonged cascade of immune dysfunction, neurological disruption, and metabolic abnormality was met with scepticism in many clinical quarters for decades. Long COVID has made that scepticism untenable. When the same post-viral pattern emerges in tens of millions of people globally — across age groups, prior health statuses, and healthcare systems — it becomes impossible to dismiss as psychosomatic or as a failure of coping. The post-viral hypothesis for ME/CFS has not merely been supported by the long COVID experience; it has been vindicated at a scale no researcher could previously have engineered.

New Money, New Momentum

Perhaps the most concrete change that long COVID has delivered for ME/CFS research is funding. In the United States, the National Institutes of Health launched its RECOVER (Researching COVID to Enhance Recovery) initiative — a programme involving billions of dollars and tens of thousands of participants — to study long COVID. While RECOVER has attracted its own criticism from patient advocates who argue it has not moved fast enough or focused sufficiently on PEM and ME/CFS-like presentations, the sheer scale of investment dwarfs anything the ME/CFS field has historically attracted.

Groups like Griffith University's National Centre for Neuroimmunology and Emerging Diseases (NCNED) in Queensland, Australia — which has spent years investigating calcium ion channel abnormalities and neuroimmunological mechanisms in ME/CFS — now find their foundational work in an increasingly crowded and well-resourced conversation. Patient communities and information networks, from Phoenix Rising to Health Rising (founded by Cort Johnson), which have kept knowledge alive through lean decades of institutional neglect, have seen their audience and relevance grow dramatically. The European Network on ME/CFS (EUROMENE) has similarly found new impetus in the post-pandemic moment.

Crucially, the biological tools being brought to bear on long COVID — detailed immunophenotyping, microbiome analysis, functional neuroimaging, autonomic testing, and more — are generating data relevant to ME/CFS. Researchers have identified persisting viral reservoirs, reactivation of latent herpesviruses including Epstein-Barr virus, evidence of microclotting, and signatures of immune dysregulation in long COVID cohorts. Each of these threads connects to hypotheses that ME/CFS researchers have been pursuing, often without adequate resources, for years.

Cautious Hope, Not Premature Celebration

It would be a disservice to long-standing ME/CFS patients to suggest that long COVID has solved anything. No cure exists. No diagnostic biomarker has yet been validated for clinical use. Many long COVID patients are discovering what ME/CFS patients have known for a long time: that medical systems are poorly equipped to support people with complex, fluctuating, post-viral illness, and that recovery, where it occurs, is slow and non-linear.

What has changed is the scientific and political context in which these illnesses exist. ME/CFS is no longer a niche concern dismissed at the margins of medicine. The infrastructure of researchers, clinicians, patient advocates, and funders now engaged with post-viral illness is larger than it has ever been. For patients navigating pacing, energy envelopes, orthostatic intolerance, and all the daily realities of ME/CFS, that shift in the landscape is real — even if, for now, it has yet to translate into treatments on a prescription pad. The lesson long COVID is teaching medicine about ME/CFS is one that patients already knew: this is a serious, biological illness, and it deserved urgent attention long before a pandemic made it impossible to look away.